Clene Inc. has announced the offering of 725,000 shares of its common stock at a price of $4.713 per share, alongside pre-funded warrants to purchase up to 17,626 shares of common stock. The offering is directed to an accredited and institutional investor pursuant to a prospectus supplement, the accompanying base prospectus, and a securities purchase agreement dated September 30, 2024. The pre-funded warrants have an offering price of $4.713 minus $0.001 per warrant, an exercise price of $0.001 per share, and are exercisable immediately upon issuance. Concurrently, Clene Inc. is conducting a private placement of unregistered warrants to purchase up to 742,626 shares of common stock to the same accredited investor. Additionally, existing stockholders and certain directors and executive officers are participating in separate concurrent private placements...Show More

Clene Inc. has announced the offering of 725,000 shares of its common stock at a price of $4.713 per share, alongside pre-funded warrants to purchase up to 17,626 shares of common stock. The offering is directed to an accredited and institutional investor pursuant to a prospectus supplement, the accompanying base prospectus, and a securities purchase agreement dated September 30, 2024. The pre-funded warrants have an offering price of $4.713 minus $0.001 per warrant, an exercise price of $0.001 per share, and are exercisable immediately upon issuance. Concurrently, Clene Inc. is conducting a private placement of unregistered warrants to purchase up to 742,626 shares of common stock to the same accredited investor. Additionally, existing stockholders and certain directors and executive officers are participating in separate concurrent private placements, purchasing restricted shares and warrants under similar terms. The offerings and private placements are part of Clene Inc.'s efforts to raise capital for general corporate purposes, including the clinical development of its lead drug candidate, CNM-Au8. The common stock and public warrants of Clene Inc. are listed on The Nasdaq Capital Market under the symbols 'CLNN' and 'CLNNW,' respectively. The offerings are expected to close on or about October 1, 2024.